Gene- and Immunotherapy for Hematological Diseases

Guest Editor
Dagmar Diloo, Düsseldorf

21 figures, 3 in color and 12 tables, 2003
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see ‘General Information’).

© Copyright 2003 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel
Contents

59 Editorial

60 Gene Therapy for Inborn and Acquired Immune Deficiency Disorders
  Engel, B.C.; Kohn, D.B. (Los Angeles, Calif.)

71 Gene Transfer Strategies for Correction of Lysosomal Storage Disorders
  d’Azzo, A. (Memphis, Tenn.)

86 Gene Therapy for Chronic Granulomatous Disease
  Goebel, W.S.; Dinauer, M.C. (Indianapolis, Ind.)

93 Hematoprotection by Transfer of Drug-Resistance Genes
  Flasshove, M.; Moritz, T.; Bardenheuer, W.; Seeber, S. (Essen)

107 Gene Therapy Targeting Hematopoietic Cells: Better Not Leave It to Chance
  Baum, C. (Hannover/Cincinnati, Ohio); von Kalle, C. (Cincinnati, Ohio)

110 Adoptive Immunotherapy in Chimeras with Donor Lymphocytes
  Guenther, W.; Ledderose, G.; Schleuning, M. (Munich)

121 Cellular Engineering of HSV-tk Transduced, Expanded T Lymphocytes for
Graft-versus-Host Disease Management
  Burger, S.R. (Chapel Hill, N.C.); Kadirosso, D.M.; Basso, L.; Bostrom, N.; Orchard, P.J.
  (Minneapolis, Minn.)

132 Alternative Concepts of Suicide Gene Therapy for Graft-versus-Host Disease
after Adoptive Immunotherapy
  Kramm, C.M. (Düsseldorf)

139 Adoptive T-Cell Therapy for EBV-Associated Post-Transplant
Lymphoproliferative Disease
  Bollard, C.M.; Savoldo, B.; Rooney, C.M.; Heslop, H.E. (Houston, Tex.)

149 Adoptive T-Cell Therapy for Epstein-Barr Virus-Positive Hodgkin’s Disease
  Huls, M.H.; Rooney, C.M.; Heslop, H.E. (Houston Tex.)

154 Chimeric T-Cell Receptors for the Targeting of Cancer Cells
  Rössig, C. (Münster); Brenner, M.K. (Houston, Tex.)

160 Leukemia Vaccines
  Glouchkova, L.; Ackermann, B.; Dilloo, D. (Düsseldorf)

171 Author Index, Vol. 110, No. 2–3, 2003

172 Subject Index, Vol. 110, No. 2–3, 2003